Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × vatalanib × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2 Sarcoma 2 Plasma cell 2 Endocrine 2 Tumor-Agnostic 1 Other solid neoplasm 1 Other hematologic neoplasm 1 NET 1 Myeloid 1 Lymphoid 1 Genitourinary 1 Gastrointestinal 1 Dermatologic 1 Classical hematology 1 CNS 1 Breast 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 18 Temozolomide 12 Everolimus 12 Nivolumab 8 Capecitabine 8 cabozantinib 7 pembrolizumab 6 Sunitinib 6 Magnetic Resonance Spectroscopy 5 lanreotide 4 gallium Ga 68 dotatate 4 Specimen Handling 4 Etoposide 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 telotristat ethyl 3 pazopanib 3 lenvatinib 3 avelumab 3 Octreotide 3 Ipilimumab 3 Injections 3 Fluorodeoxyglucose F18 3 Cyclophosphamide 3 Cisplatin 3 Carboplatin 3 Bevacizumab 3 surufatinib 2 sintilimab 2 fosbretabulin 2 fludarabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00590343 2011-06-29

PTK787

Louisiana State University Health Sciences Center in New Orleans

Phase 2 Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡